Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MGAT1 | P26572 | 1/20 | 0.30 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900938 | 0.84 | ELANE (0.43) | ITGALFPR2ELANEAR | |
| SCHEMBL9900172 | 0.81 | AR (0.56) | ITGALARRAB9AALDH1A1 | |
| SCHEMBL11719337 | 0.80 | ITGAL (0.62) | ITGALFPR2ELANEARNPC1 | |
| SCHEMBL14157359 | 0.78 | ELANE (0.43) | ITGALFPR2ELANEARNPC1 | |
| SCHEMBL19846865 | 0.78 | ELANE (0.58) | ITGALFPR2ELANEARALDH1A1 | |
| SCHEMBL31657833 | 0.77 | FPR2 (0.37) | ITGALFPR2ELANENPC1RAB9A | |
| SCHEMBL31009069 | 0.77 | FPR2 (0.37) | ITGALFPR2ELANENPC1RAB9A | |
| SCHEMBL21953171 | 0.77 | FPR2 (0.37) | ITGALFPR2ELANENPC1RAB9A | |
| SCHEMBL16459363 | 0.76 | AR (0.39) | ITGALFPR2ELANEARNPC1 | |
| SCHEMBL11722346 | 0.72 | ITGAL (0.44) | ITGALFPR2ELANEARNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11541052-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-01-03 | — | — | US | disclosed |
| US-11541052-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20210023084-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2021-01-28 | — | — | US | disclosed |
| US-20210023084-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2021-01-28 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| EP-2718285-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| CN-103328467-A | Hydantoin derivatives useful as KV3 inhibitors | AUTIFONY THERAPEUTICS LTD | 2013-09-25 | — | — | CN | disclosed |
| WO-2013083994-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012168710-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | ITGAL 3033/4885FPR2 3727/4885ELANE 3778/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | ITGAL 3033/4885FPR2 3727/4885ELANE 3778/4885 |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | ITGAL 3350/4885FPR2 3611/4885ELANE 3915/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | ITGAL 3508/4885FPR2 3621/4885ELANE 3602/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | ITGAL 3033/4885FPR2 3727/4885ELANE 3778/4885 |
| US-20210023084-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | ITGAL 1960/4885FPR2 1167/4885ELANE 3693/4885 |
| US-11541052-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | ITGAL 1970/4885FPR2 1587/4885ELANE 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.